Blood Research Institute, Versiti Blood Center of Wisconsin, Milwaukee, WI, USA.
Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
J Clin Lipidol. 2021 Sep-Oct;15(5):724-731. doi: 10.1016/j.jacl.2021.08.002. Epub 2021 Aug 10.
Alteration in blood triglyceride levels have been found in patients with coronavirus disease 2019 (COVID-19). However, the association between hypertriglyceridemia and mortality in COVID-19 patients is unknown.
To investigate the association between alteration in triglyceride level and mortality in hospitalized COVID-19 patients.
We conducted a retrospective study of 600 hospitalized patients with COVID-19 diagnosis (ICD10CM:U07.1) and/or SARS-CoV-2 positive testing results between March 1, 2020 and December 21, 2020 at a tertiary academic medical center in Milwaukee, Wisconsin. De-identified data, including demographics, medical history, and blood triglyceride levels were collected and analyzed. Of the 600 patients, 109 patients died. The triglyceride value on admission was considered the baseline and the peak was defined as the highest level reported during the entire period of hospitalization. Hypertriglyceridemia was defined as greater than 150 mg/dl. Logistic regression analyses were performed to evaluate the association between hypertriglyceridemia and mortality.
There was no significant difference in baseline triglyceride levels between non-survivors (n = 109) and survivors (n = 491) [Median 127 vs. 113 mg/dl, p = 0.213]. However, the non-survivors had significantly higher peak triglyceride levels during hospitalization [Median 179 vs. 134 mg/dl, p < 0.001]. Importantly, hypertriglyceridemia independently associated with mortality [odds ratio=2.3 (95% CI: 1.4-3.7, p = 0.001)], after adjusting for age, gender, obesity, history of hypertension and diabetes, high CRP, high leukocyte count and glucocorticoid treatment in a multivariable logistic regression model.
Hypertriglyceridemia during hospitalization is independently associated with 2.3 times higher mortality in COVID-19 patients. Prospective studies are needed to independently validate this retrospective analysis.
新冠肺炎(COVID-19)患者的血液甘油三酯水平发生了变化。然而,高甘油三酯血症与 COVID-19 患者死亡率之间的关系尚不清楚。
探讨住院 COVID-19 患者甘油三酯水平变化与死亡率之间的关系。
我们对 2020 年 3 月 1 日至 2020 年 12 月 21 日期间在威斯康星州密尔沃基市的一家三级学术医疗中心住院的 600 名 COVID-19 诊断(ICD10CM:U07.1)和/或 SARS-CoV-2 阳性检测结果的患者进行了回顾性研究。收集并分析了包括人口统计学、病史和血液甘油三酯水平在内的去识别数据。在 600 名患者中,有 109 名患者死亡。入院时的甘油三酯值被视为基线,峰值定义为整个住院期间报告的最高水平。高甘油三酯血症定义为大于 150mg/dl。进行逻辑回归分析以评估高甘油三酯血症与死亡率之间的关系。
非幸存者(n=109)和幸存者(n=491)的基线甘油三酯水平无显著差异[中位数 127 与 113mg/dl,p=0.213]。然而,非幸存者在住院期间的甘油三酯峰值显著升高[中位数 179 与 134mg/dl,p<0.001]。重要的是,在校正年龄、性别、肥胖、高血压和糖尿病史、高 C 反应蛋白、高白细胞计数和糖皮质激素治疗后,高甘油三酯血症与死亡率独立相关[比值比=2.3(95%置信区间:1.4-3.7,p=0.001)],在多变量逻辑回归模型中。
住院期间的高甘油三酯血症与 COVID-19 患者的死亡率增加 2.3 倍独立相关。需要前瞻性研究来独立验证这项回顾性分析。